Novavax Announces Management Promotion

GAITHERSBURG, Md., June 15, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Chris Dunne has been named Vice President, Finance. Mr. Dunne joined Novavax as the Executive Director, Finance in January 2010, with responsibility for financial reporting.  Prior to joining Novavax, he was Senior Director, Finance at Ore Pharmaceuticals (previously known as Gene Logic), a publicly traded biotechnology company, from 1996 until joining Novavax in 2010.

Mr. Dunne’s prior experience includes roles as a Senior Project Accountant for Akridge, where he was responsible for the accounting activities of a portfolio of commercial real estate partnerships and corporations located in the Washington, D.C., metropolitan area and with Deloitte & Touche LLP, where he managed audits for a number of public and private companies, including preparation for initial public offerings and SEC reporting. Mr. Dunne received a B.S. degree in Business Management, Accounting from the University of Maryland and is a Certified Public Accountant.

“Chris was an instrumental part of the team that secured our $179 million contract with HHS-BARDA and his leadership in finance and accounting has been central to our growth as a company,” said Stanley C. Erck, President and CEO. “Chris’ expertise will continue to be important as we advance our programs to late-stage clinical trials and ultimately seek to bring our RSV F Vaccine to market.”

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.

Contact:
Novavax, Inc.Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
[email protected]
240-268-2000

Russo Partners, LLCDavid SchullTodd Davenport, Ph.D.
[email protected][email protected]
212-845-4271